UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 121,056 Shares of Humana Inc. (NYSE:HUM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 978,010 shares of the insurance provider's stock after buying an additional 121,056 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.81% of Humana worth $248,131,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter worth $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the 4th quarter worth $30,000. LFA Lugano Financial Advisors SA increased its holdings in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana in the 4th quarter worth $33,000. Finally, Transce3nd LLC bought a new stake in shares of Humana in the 4th quarter worth $38,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

NYSE HUM traded up $3.47 on Wednesday, hitting $230.08. 688,907 shares of the company traded hands, compared to its average volume of 1,775,482. The company has a market capitalization of $27.77 billion, a price-to-earnings ratio of 23.12, a P/E/G ratio of 2.05 and a beta of 0.49. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The business's 50 day moving average price is $259.52 and its 200-day moving average price is $267.76. Humana Inc. has a 52-week low of $212.45 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. During the same quarter last year, the company earned $7.23 EPS. The firm's quarterly revenue was up 8.4% on a year-over-year basis. Equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.54%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio (DPR) is currently 25.04%.

Analysts Set New Price Targets

A number of analysts have commented on the company. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Truist Financial cut their price objective on Humana from $325.00 to $305.00 and set a "hold" rating for the company in a report on Monday, May 12th. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. JPMorgan Chase & Co. cut their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Finally, Wall Street Zen raised Humana from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Seventeen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Humana has an average rating of "Hold" and an average target price of $286.81.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.